+

WO2006017759A3 - Tumor endothelial marker-1 (tem1) binding antibodies and uses thereof - Google Patents

Tumor endothelial marker-1 (tem1) binding antibodies and uses thereof Download PDF

Info

Publication number
WO2006017759A3
WO2006017759A3 PCT/US2005/027938 US2005027938W WO2006017759A3 WO 2006017759 A3 WO2006017759 A3 WO 2006017759A3 US 2005027938 W US2005027938 W US 2005027938W WO 2006017759 A3 WO2006017759 A3 WO 2006017759A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
tem1
endothelial
disclosed
endothelial marker
Prior art date
Application number
PCT/US2005/027938
Other languages
French (fr)
Other versions
WO2006017759A2 (en
Inventor
Beverly Teicher
Bruce Roberts
Shiro Kataoka
Tomoyuki Tahara
Nakayuki Honma
Original Assignee
Kirin Brewery
Genzyme Corp
Beverly Teicher
Bruce Roberts
Shiro Kataoka
Tomoyuki Tahara
Nakayuki Honma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kirin Brewery, Genzyme Corp, Beverly Teicher, Bruce Roberts, Shiro Kataoka, Tomoyuki Tahara, Nakayuki Honma filed Critical Kirin Brewery
Publication of WO2006017759A2 publication Critical patent/WO2006017759A2/en
Publication of WO2006017759A3 publication Critical patent/WO2006017759A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to antibodies that bind tumor endothelial marker 1 (TEM1) and effectively inhibit angiogenesis, tumor growth, or both. Pharmaceutical compositions and uses thereof for the treatment of angiogenesis-associated diseases including cancer, polycystic kidney disease, diabetic retinopathy, age-related macular degenerations, rheumatoid arthritis, and psoriasis are also disclosed. Also disclosed are methods of identifying such antibodies by assessing (1) the inhibitory activity of candidate antibodies in proliferation and tube formation assays using endothelial cells, endothelial precursor cells and pericytes, and (2) the antibody-dependent cellular cytotoxic, phagocytosis, and complement-dependent cytotoxic activities of candidate antibodies.
PCT/US2005/027938 2004-08-05 2005-08-05 Tumor endothelial marker-1 (tem1) binding antibodies and uses thereof WO2006017759A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59935904P 2004-08-05 2004-08-05
US60/599,359 2004-08-05

Publications (2)

Publication Number Publication Date
WO2006017759A2 WO2006017759A2 (en) 2006-02-16
WO2006017759A3 true WO2006017759A3 (en) 2006-07-06

Family

ID=35839950

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/027938 WO2006017759A2 (en) 2004-08-05 2005-08-05 Tumor endothelial marker-1 (tem1) binding antibodies and uses thereof

Country Status (2)

Country Link
TW (1) TW200630381A (en)
WO (1) WO2006017759A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592430B2 (en) 2003-09-10 2009-09-22 Amgen Fremont Antibodies to M-CSF
JP7094893B2 (en) 2016-02-05 2022-07-04 メディアファルマ・エッセ・エッレ・エッレ Endosialin binding antibody

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006116451A2 (en) 2005-04-22 2006-11-02 Morphotek, Inc. Antibodies with immune effector activity and that internalize in endosialin-positive cells
CN101089178B (en) * 2006-06-12 2012-05-23 杭州北斗生物技术有限公司 Beta-lactamase, preparation method and application thereof
KR101529334B1 (en) 2007-04-05 2015-06-16 모르포테크, 인크. Methods for inhibiting the binding of endosialin to ligands
WO2010037124A1 (en) * 2008-09-29 2010-04-01 The Trustees Of The University Of Pennsylvania Tumor vascular marker-targeted vaccines
CA2738545A1 (en) 2008-10-01 2010-04-08 Micromet Ag Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxcd3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
US9556272B2 (en) 2009-11-11 2017-01-31 The Trustees Of The University Of Pennsylvania Anti-TEM1 antibodies and uses thereof
AU2012335070A1 (en) * 2011-11-11 2014-05-29 Bio-Ess Laboratories, Llc Kit comprising serum replacement and labile factors
JP6285414B2 (en) * 2012-03-30 2018-02-28 モルフォテック， インコーポレイテッド TEM-1 diagnostic antibody
US9783610B2 (en) * 2012-04-27 2017-10-10 The Trustees Of The University Of Pennsylvania Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof
WO2016205618A1 (en) * 2015-06-19 2016-12-22 Morphotek, Inc. Cys80 conjugated immunoglobulins
CN106591208A (en) * 2016-12-07 2017-04-26 南昌大学 Vector strain of recombinant single-chain antibody expressing DNase I, AIF or integrating toxins, and application of strain
GB201702926D0 (en) * 2017-02-23 2017-04-12 Univ Birmingham Modulators
EP4393952A1 (en) * 2021-08-26 2024-07-03 Kyowa Kirin Co., Ltd. Bispecific antibody that binds to cd116 and cd131

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
US20040164213A1 (en) * 2003-02-21 2004-08-26 Copeland Stephan Mechanical arm with spring counterbalance
US6849425B1 (en) * 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
US20050058649A1 (en) * 2002-12-02 2005-03-17 Landes Gregory M. Antibodies directed to phospholipase A2 and uses thereof
US20050266008A1 (en) * 2004-03-29 2005-12-01 Medarex, Inc. Human anti-IRTA-5 antibodies

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849425B1 (en) * 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
US20050058649A1 (en) * 2002-12-02 2005-03-17 Landes Gregory M. Antibodies directed to phospholipase A2 and uses thereof
US20040164213A1 (en) * 2003-02-21 2004-08-26 Copeland Stephan Mechanical arm with spring counterbalance
US20050266008A1 (en) * 2004-03-29 2005-12-01 Medarex, Inc. Human anti-IRTA-5 antibodies

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592430B2 (en) 2003-09-10 2009-09-22 Amgen Fremont Antibodies to M-CSF
JP7094893B2 (en) 2016-02-05 2022-07-04 メディアファルマ・エッセ・エッレ・エッレ Endosialin binding antibody

Also Published As

Publication number Publication date
TW200630381A (en) 2006-09-01
WO2006017759A2 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
WO2006017759A3 (en) Tumor endothelial marker-1 (tem1) binding antibodies and uses thereof
US11426468B2 (en) Cysteine linked nanobody dimers
TWI526223B (en) Humanized axl antibodies
WO2005054273A3 (en) Humanized antibodies against vascular endothelial growth factor
US11021544B2 (en) Nanobody dimers linked via C-terminally engineered cysteins
Singer et al. Generation of a canine anti-EGFR (ErbB-1) antibody for passive immunotherapy in dog cancer patients
JP5766296B2 (en) Polypeptide-polynucleotide complexes and their use in targeted delivery of effector components
WO2005080431A3 (en) Monoclonal antibodies that specifically bind to folate receptor alpha
MX2010005966A (en) Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (ptk7).
EP3652216A1 (en) Checkpoint inhibitor bispecific antibodies
WO2006089141A3 (en) Antibodies against cxcr4 and methods of use thereof
WO2006002177A3 (en) Interferon alpha receptor 1 antibodies and their uses
WO2008031056A3 (en) Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2008047242A8 (en) Novel anti-cd38 antibodies for the treatment of cancer
WO2007067992A3 (en) Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
WO2014012007A4 (en) Rspo3 binding agents and uses thereof
MA31143B1 (en) MODIFIED SOLUBLE FGF / FC RECEPTOR FUSION PROTEINS HAVING IMPROVED BIOLOGICAL ACTIVITY
CN105829543A (en) Glycoengineered antibody, antibody-conjugate and methods for their preparation
EP3530736A3 (en) Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
UA116614C2 (en) FACTOR ANTIBODY AND ITS APPLICATION
WO2005012493A3 (en) Anti-cd19 antibodies
EP2535355A3 (en) Antibodies against CD38 for treatment of multiple myeloma
WO2006034455A3 (en) Polipeptide compounds for inhibiting angiogenesis and tumor growth
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
JP2017527562A (en) Cytotoxic benzodiazepine derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载